Iran Unveils Several New Knowledge-Based Pharmaceutical Products
Six new pharmaceutical products of the knowledge-based company were unveiled in a ceremony participated by Dehqani Firouzabadi, Minister of Industry, Mine and Trade Abbas Aliabadi, and Head of Iran's Food and Drug Administration Heidar Mohammadi.
The products included ‘Volgat Eczema (chewable tablet)’, ‘Volgat D3 (oral drops)’, ‘Volgat Multi (chewable tablet)’, ‘Biobion (oral liquid vial)’, ‘Rojuvit (chewable tablet)’, ‘Ibrutinib (tablet)’ and the 3 primary ingredients of ‘Tofacitinib’, ‘Edaravon’, and ‘Ibrutinib’.
“The pharmaceutical raw materials produced by our company are classified as high-risk materials in terms of health-oriented exposure limits,” said Sahar Bahmani, the managing director of the knowledge-based company.
She noted that production and working with these materials has international requirements and rules, adding, “These products are in the field of cancer treatment and probiotics which are among the special medicine.”
In a relevant development in January, specialists of another knowledge-based company in Iran had also succeeded in finding the formulation and producing the active ingredients used in pharmaceutical industry by applying the synthesis technology.
“One of the most important complications in production of active ingredients in most countries is the technology required for the pre-production process. In fact, certain steps should be taken by researchers to reach the final active ingredient,” Maryam Jahangir, an expert and representative of the knowledge-based company, told ANA.
She added that the remarkable thing about the active ingredient is that in addition to their indigenization, they have a completely exclusive application in the pharmaceutical industry.
“The special technology used in the production process of the active ingredient is the advanced synthesis of active medicinal substances,” Jahangir said.
She also noted that at present, almost all manufacturers of Clobetasol propionate use the active ingredient produced by the knowledge-based company, adding that during the coronavirus outbreak in Iran, the pharmaceutical manufacturers of Dexamethasone were also a special customer of the active ingredients.
4155/v
